ulifloxacin

Ulifloxacin is a broad-spectrum fluoroquinolone antibiotic and the active metabolite of the prodrug prulifloxacin. It exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. Originally synthesized by Nippon Shinyaku, ulifloxacin demonstrates potent activity against a wide range of Gram-positive and Gram-negative pathogens, including *Pseudomonas aeruginosa*, *Escherichia coli*, and *Staphylococcus aureus*. While the prodrug prulifloxacin is administered orally and rapidly converted to ulifloxacin by systemic esterases (primarily paraoxonase), ulifloxacin is the pharmacologically active moiety responsible for the clinical efficacy in treating infections such as urinary tract infections, acute exacerbations of chronic bronchitis, and acute bacterial rhinosinusitis.

Other names

NM394NM-394NM 394